Effect of hydrothorax EGFR gene mutation and EGFR-TKI targeted therapy on advanced non-small cell lung cancer patients.

about

Metuzumab enhanced chemosensitivity and apoptosis in non-small cell lung carcinoma.Bevacizumab and gefitinib enhanced whole-brain radiation therapy for brain metastases due to non-small-cell lung cancer.

P2860

Q37662007-089243C2-D642-483E-9B28-94D7068AD89F Q47142558-CCD04431-0AF7-40C1-BA04-2E5858EBEA88

P2860

Effect of hydrothorax EGFR gene mutation and EGFR-TKI targeted therapy on advanced non-small cell lung cancer patients.

Item

http://www.wikidata.org/entity/Q36524729

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Effect of hydrothorax EGFR gen ...... all cell lung cancer patients.

@ast

Effect of hydrothorax EGFR gen ...... all cell lung cancer patients.

@en

type

Item

label

Effect of hydrothorax EGFR gen ...... all cell lung cancer patients.

@ast

Effect of hydrothorax EGFR gen ...... all cell lung cancer patients.

@en

prefLabel

Effect of hydrothorax EGFR gen ...... all cell lung cancer patients.

@ast

Effect of hydrothorax EGFR gen ...... all cell lung cancer patients.

@en

P1476

Effect of hydrothorax EGFR gen ...... all cell lung cancer patients.

@en

P2093

B O Zhou

http://www.w3.org/2001/XMLSchema#string

Chenhong Huang

http://www.w3.org/2001/XMLSchema#string

Hongfei Zhao

http://www.w3.org/2001/XMLSchema#string

Jun Nie

http://www.w3.org/2001/XMLSchema#string

Weidong Yang

http://www.w3.org/2001/XMLSchema#string

Y E Huang

http://www.w3.org/2001/XMLSchema#string

P2860

Review of the current targeted therapies for non-small-cell lung cancer

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer.

Epidermal growth factor receptor: mechanisms of activation and signalling.

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.

P304

1413-1417

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2015.4066

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

288903507

http://www.w3.org/2001/XMLSchema#string

P698

26893752

http://www.w3.org/2001/XMLSchema#string

P932

4734265

http://www.w3.org/2001/XMLSchema#string

Effect of hydrothorax EGFR gene mutation and EGFR-TKI targeted therapy on advanced non-small cell lung cancer patients.

about

P2860

P2860

Effect of hydrothorax EGFR gene mutation and EGFR-TKI targeted therapy on advanced non-small cell lung cancer patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932